NEW YORK, March 15 – Arena Pharmaceuticals has enlisted the help of Celera’s databases and bioinformatics tools to identify G protein-coupled receptors (GPCRs), the companies said Thursday.
Financial terms of Arena's multi-year subscription to the Celera Discovery System were not disclosed, but Celera has previously said that non-academic subcribers pay $5 million to $15 million a year. After signing Arena, Celera now has eight known commercial subscribers.
Arena focuses its discovery efforts on finding small molecules that regulate GPCRs through its CART system, a method for analyzing how a GPCR responds to interacting ligands. The company hopes to screen all of the therapeutically-relevant GPCRs in the next three to five years.
"Current estimates suggest, and we believe, that therapeutically relevant GPCRs comprise about 600 to 900 of the estimated 30,000 human genes within the human genome,” Jack Lief, Arena’s CEO, said in a statement. “Arena currently has about two-thirds of these in-house available for drug discovery, and we believe that we can capture a substantial number of the remaining GPCRs in the human genome from Celera's database.”Most recently, Celera integrated gene expression data from Lynx Therapeutics into its databases.